Understanding SRRM1: A Potential Drug Target or Biomarker (G10250)

Target Name: SRRM1

NCBI ID: G10250

SRRM1

Understanding SRRM1: A Potential Drug Target or Biomarker

SRRM1 (SRRM1 variant 2) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The gene is located on chromosome 12 and encodes a protein known as SRRM1, which is involved in various cellular processes, including cell adhesion, migration, and invasion.

Recent studies have suggested that SRRM1 may be a promising drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One of the main reasons for this is the fact that SRRM1 is involved in various cellular processes that are associated with the development and progression of these diseases. For example, SRRM1 has been shown to be involved in the regulation of cell adhesion, which is a critical process that helps cells stick together and form tissues. In cancer, this process can be disrupted, leading to the development of tumors.

Another potential mechanism by which SRRM1 may be involved in the development and progression of neurodegenerative diseases is its role in the regulation of cell migration. This process is critical for the development and progression of many neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. By regulating cell migration, SRRM1 may be involved in the progression of these diseases, and could potentially be a useful drug target or biomarker for these conditions.

In addition, SRRM1 has also been shown to be involved in the regulation of inflammation, which is a critical process that helps the immune system fight off infections and diseases. This is important because many autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis, are characterized by inflammation. By regulating inflammation, SRRM1 may be involved in the development and progression of these disorders.

Overall, SRRM1 is a gene that has the potential to be a drug target or biomarker for a variety of diseases. Its involvement in various cellular processes that are associated with the development and progression of these diseases makes it an attractive target for drug development. Further research is needed to fully understand the role of SRRM1 in these processes and to determine its potential as a drug target or biomarker.

Protein Name: Serine And Arginine Repetitive Matrix 1

Functions: Part of pre- and post-splicing multiprotein mRNP complexes. As a component of the minor spliceosome, involved in the splicing of U12-type introns in pre-mRNAs (Probable). Involved in numerous pre-mRNA processing events. Promotes constitutive and exonic splicing enhancer (ESE)-dependent splicing activation by bridging together sequence-specific (SR family proteins, SFRS4, SFRS5 and TRA2B/SFRS10) and basal snRNP (SNRP70 and SNRPA1) factors of the spliceosome. Stimulates mRNA 3'-end cleavage independently of the formation of an exon junction complex. Binds both pre-mRNA and spliced mRNA 20-25 nt upstream of exon-exon junctions. Binds RNA and DNA with low sequence specificity and has similar preference for either double- or single-stranded nucleic acid substrates

The "SRRM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SRRM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets